Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development. 

The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics knowledge to advance molecular insights supporting the clinical development of TH9619. 

TH9619, developed by One-carbon Therapeutics, is a first-in-class, potent small-molecule inhibitor of overexpressed enzymes MTHFD1 and MTHFD2. This inhibition in cancer cells induces toxic folate trapping, starving tumours of the critical DNA building block thymidine, leading to DNA damage and causing cancer cell death.  

As part of the collaboration, One-carbon Therapeutics will use Tempus’ analytical services to characterise the expression landscape across prioritised solid tumour indications. By integrating RNA sequencing data with clinical variables, the teams aim to uncover molecular insights to develop TH9619.  

“Understanding the molecular dynamics of one-carbon metabolism across tumour types and treatment settings is fundamental to advancing TH9619 with precision,” said Ana Slipicevic, Chief Executive Officer at One-carbon Therapeutics.  

“Tempus’ depth of molecular data and analytical rigour enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimise development.” 

“At Tempus, our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances,” said Ezra Cohen, Chief Medical Officer, Oncology, at Tempus.  

“Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterising the metabolic signatures across diverse tumour types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”     

The post Collaboration to advance precision oncology therapy  appeared first on Drug Discovery World (DDW).